Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

This study aimed to evaluate the burden of HPV-related hospitalization and mortality in Greece, with a focus on invasive cervical cancer and lip, oral cavity, and pharyngeal (LOCP) cancers. A retrospective query using data from the Greek Statistical Office and Eurostat was executed. The query included hospital admission and standardized mortality rates (SDRs) on cervical dysplasia and cervical, vulvar, and vaginal; anal; penile; and LOCP cancers. The hospitalization rate for invasive cervical cancer decreased over time, exhibiting a sharp decrease after 2010, while the hospitalization rate for LOCP cancer decreased after 2011, preceded by a sustained increase from 1996. The hospitalization rate of HPV-attributable diseases in total showed a declining tendency between 2013 and 2017. SDR due to cervical cancer showed a slightly decreasing trend in Greece and the European Union, while SDR due to LOCP cancer showed a slightly increasing trend in Greece, but a decrease in the European Union. The decline in hospitalization rates for HPV-related disease in Greece, especially for cervical cancer and dysplasia, and also the declining SDR for invasive cervical cancer in Greece and the EU, are indications of the positive public health impact of screening programs and the implementation of HPV vaccination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11858740PMC
http://dx.doi.org/10.3390/pathogens14020197DOI Listing

Publication Analysis

Top Keywords

cervical cancer
20
invasive cervical
12
hospitalization rate
12
cervical
8
lip oral
8
oral cavity
8
cavity pharyngeal
8
cancer
8
locp cancers
8
cancer decreased
8

Similar Publications

Cervical cancer remains a significant public health issue, ranking as the fourth most common cancer in women globally. In the Netherlands, cervical cancer incidence declined steadily from 1989 to 2001 but increased between 2001 and 2007. This study updates trends in cervical cancer incidence from 1989 to 2023 in the Netherlands and evaluates the impact of screening practices and participation rates in the national population-based screening program.

View Article and Find Full Text PDF

Rationale: Cervical cancer is the fourth most common cancer affecting women worldwide, caused by persistent infection with oncogenic human papillomavirus (HPV) types. While HPV infections usually resolve spontaneously, persistent infections with high-risk HPV types can progress to premalignant glandular or - mostly - squamous intraepithelial lesions, usually classified in cervical intraepithelial neoplasia (CIN). Women with CIN 2 and CIN 3 (i.

View Article and Find Full Text PDF

Cervical cancer continues to pose a significant global health challenge, highlighting the urgent need for accurate and efficient diagnostic techniques. Recent progress in deep learning has demonstrated considerable potential in improving the detection and classification of cervical cancer. This review presents a thorough analysis of deep learning methods utilized for cervical cancer diagnosis, with an emphasis on critical approaches, evaluation metrics, and the ongoing challenges faced in the field.

View Article and Find Full Text PDF

Background: Cervical cancer (CC) is a leading cause of cancer-related deaths worldwide, emphasizing the need for accurate and efficient diagnostic tools. Traditional methods of cervical cell classification are time-consuming and susceptible to human error, highlighting the need for automated solutions.

Materials And Methods: This study introduces the modified hierarchical deep feature fusion (HDFF) method for cervical cell classification using the SIPaKMeD and Herlev datasets.

View Article and Find Full Text PDF

Case Report: Immune-mediated acute liver failure induced by tislelizumab in a patient with advanced cervical cancer.

Front Oncol

August 2025

Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.

View Article and Find Full Text PDF